Hypertrophic obstructive cardiomyopathy is a dynamic obstruction of the left ventricular outflow tract caused by septal hypertrophy and systolic anterior motion of the mitral valve. When the condition cannot be controlled by medical therapy the most frequently used surgical approach is left ventricular myotomy-myectomy. Mitral valve replacement (to correct another mechanism of obstruction) is another surgical option; however, its use for this condition is controversial. We review the long-term results of patients who underwent limited left ventricular myotomy-myectomy and mitral valve replacement at our institution. Eighteen patients who had hypertrophic obstructive cardiomyopathy and severe mitral insufficiency underwent surgery between 1978 and 1983: 7 were men and 11 were women (mean age, 41.8 +/- 10.5 years). Preoperatively, most of the patients (78.8%) were in New York Heart Association functional class III or IV. The operation consisted of a shallow myectomy of the hypertrophied septum and mitral valve replacement. One patient died in the hospital (5.5%); 3 patients died later during follow-up. The remaining 14 patients are alive and in good condition (mean follow-up, 21.9 +/- 1.7 years). Functional class improved postoperatively in all surviving patients. The mean left ventricular outflow tract gradient fell from 78.1 +/- 20.9 mmHg preoperatively to 9.4 +/- 5.2 mmHg postoperatively (P <0.001). At present, surgical treatment of hypertrophic obstructive cardiomyopathy does not include mitral valve replacement. However, our long-term results show that limited ventricular myectomy and mitral valve replacement predictably and consistently lower the left ventricular outflow tract gradient and resolve the mitral valve insufficiency.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC427372 | PMC |
Surg Pract Sci
June 2023
Cardiovascular Research & Innovation, School of Medicine, University of Galway, Galway, Ireland.
Higher and prohibitive mitral valve disease surgical scenarios are preferred cases for transcatheter mitral valve replacement as they offer unrelenting mitral valve regurgitation reduction. This review entails medical technologies that are evolving bioprosthetic devices for mitral valve repair and replacement purposes. Transcatheter mitral valve replacement is compared with transcatheter aortic valve implantation based on the etiology and driving factors.
View Article and Find Full Text PDFFront Cardiovasc Med
January 2025
Department of Cardiovascular Surgery, Gaozhou People's Hospital, Gaozhou, Guangdong, China.
Objective: The objective of this study was to improve long-term postoperative survival in a porcine cardiac valve surgery model by utilizing cardiopulmonary bypass (CPB) via left thoracotomy. The study aimed to share refined techniques and insights accumulated over years at a single-center animal clinical trial facility.
Method: A total of 196 Chinese Large White pigs weighing between 60 and 75 kg were used in the study.
BMC Neurol
January 2025
Department of Neurology, LMU University Hospital, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Background: Purulent meningitis poses a significant clinical challenge with high mortality. We present the case of a 54-year-old female transferred to our emergency department with suspected bacterial meningitis, later diagnosed as an Austrian syndrome.
Case Presentation: The patient exhibited subacute somnolence, severe headache, nausea and fever.
J Cardiothorac Vasc Anesth
January 2025
Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:
Objectives: This systematic review aims to tabulate and analyze the published literature regarding pulmonary artery catheter (PAC) entrapment during cardiac surgery.
Design: Systematic review.
Setting: Case reports and series.
Cardiovasc Interv Ther
January 2025
Heart Valve Center, IRCCS San Raffaele, Milan, Italy.
Background: Treatment of residual mitral regurgitation (MR) with different percutaneous devices after transcatheter edge-to-edge repair (TEER) has been reported as an alternative option to reclipping or surgery. This review aims at describing the different transcatheter strategies available and their results when managing residual MR after TEER.
Methods: A literature search was undertaken across Pubmed, ScienceDirect, SciELO, DOAJ, and Cochrane library databases, to identify article reporting patients with post-TEER residual MR managed by a transcatheter approach that did not involve only the implantation of new clips.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!